Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.
Frequently asked questions
What sector does Defence Therapeutics Inc. (DTC) operate in?
Defence Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Defence Therapeutics Inc. (DTC) current stock price?
As of the latest data, Defence Therapeutics Inc. stock price is €0.23, with a previous close of €0.23. Defence Therapeutics Inc. lost -€0.01 in the last trading session, representing a -2.59% loss.
What is Defence Therapeutics Inc. (DTC) current market capitalization?
Defence Therapeutics Inc. market cap is approximately 17.13 million.
What is Defence Therapeutics Inc. (DTC) Earnings Per Share (EPS)?
The trailing EPS is -€0.07.
Does Defence Therapeutics Inc. (DTC) pay dividends?
No. Defence Therapeutics Inc. does not pay a dividend.
What is Defence Therapeutics Inc. (DTC) beta (volatility) score?
Defence Therapeutics Inc. has a beta of 1.510, suggesting it is more volatile than the market.
